Sobi strengthens cancer portfolio with $580m deal

Дата публикации: 12-08-2026 13:32:15

Основное содержимое страницы с новостью.

Sobi has entered into a strategic partnership with French biotech company Innate Pharma for lacutamab, a drug candidate being developed to treat cutaneous T-cell lymphoma.

August 12, 2026 3:32 PM

The deal could be worth up to $580m excluding future royalty payments, according to a press release.

The agreement includes an upfront payment of $75m. Innate Pharma could also receive $40m in near-term development milestone payments and up to a further $465m linked to development rights and regulatory and commercial milestones. The company will also receive tiered double-digit royalties on net sales.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma	0	5	09-03-2026
2	Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment	0	7.09	26-03-2026
3	Novartis is buying a U.K. cancer drug startup for up to $1.5 billion	0	7	06-07-2026
4	FT: AstraZeneca приобретет американскую биотехнологическую компанию CinCor	0	0	09-01-2023
5	Baker McKenzie Advises Sino Biopharm on up to US$1.53 Billion Exclusive License Agreement with Sanofi for Rovadicitinib	0	15.88	12-03-2026
6	AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger	0	8.62	03-08-2026
7	Французская Orano заключила договор с Росатомом стоимостью €40 млн	0	0	10-12-2019
8	Бельгийская Solvay может продать свою долю в "Русвиниле" "Сибуру" за около €430 млн	0	0	03-03-2023
9	Saniona’s neurology collaboration advances as AstronauTx Exercises acquisition option	0	10	12-08-2026
10	Ericsson покупает Vonage	0	0	22-11-2021

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10. Источник: www.magasinetpleje.dk.